Research programme: cellspan organ implants - Biostage/Mayo Clinic

Drug Profile

Research programme: cellspan organ implants - Biostage/Mayo Clinic

Alternative Names: Cellspan bronchial implant; Cellspan oesophageal implant; Cellspan tracheal implant

Latest Information Update: 03 Dec 2016

Price : $50

At a glance

  • Originator Biostage
  • Developer Biostage; Mayo Clinic
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 01 Dec 2016 Research programme: cellspan organ implants - Biostage/Mayo Clinic receives Orphan Drug status for Cancer in USA
  • 11 Aug 2016 Preclinical trials in Cancer in USA (Implant) before August 2016
  • 11 Aug 2016 Biostage announces intention to submit IND to US FDA for oesophageal implant by end of 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top